SHINE and EDH enter distribution agreement for SHINE’s non-carrier added Lu-177

JANESVILLE, Wis. & ISTANBUL Turkey, May 25, 2021 – EDH Nuclear Medicine and Healthcare Services Ltd. Co. and SHINE Medical Technologies LLC today announced that they have entered into a distribution agreement enabling EDH to act as a SHINE-authorized distributor for selected countries.


Under the agreement, EDH will sell and distribute SHINE’s non-carrier-added, cGMP lutetium-177, or Lu-177, manufactured in Janesville, Wis.


Lu-177 is a low-energy beta-particle emitter that works by directly irradiating cancer cells after being delivered to the cancer site by a targeting molecule. Lu-177 is used to treat neuroendocrine cancers and also shows promise for the treatment of metastatic prostate and other cancers. SHINE’s Lu-177 production process enables the company to produce the high specific activity, non-carrier-added Lu-177 required by today’s customers.


“At EDH, we are keen to provide state-of-the-art theranostic products and solutions to our stakeholders and SHINE’s n.c.a Lu-177 will enable us to offer high specific activity Lu-177 to patientswhile addressing hospitals’ risks associated with waste management ,” said Hasan Ulas Ozcan, general manager of EDH Nuclear Medicine and Healthcare Services. “We are happy to partner with an innovative company like SHINE, which is aiming to become the world’s leading producer of medical isotopes, and we hope to extend our regions of operation with SHINE after successfully launching SHINE’s n.c.a Lu-177 in selected countries.”


“SHINE’s Lu-177 has the potential to improve the patient outcomes around the world with certain cancers,” said Katrina Pitas, vice president and general manager of SHINE Therapeutics. “EDH is a strong partner for SHINE. Hasan and his team know the Eurasia region well and we look forward to working with them to ensure patients have access to this promising therapeutic isotope.”


About EDH Nuclear Medicine and Healthcare Services


EDH is the most innovative Service Integrator in the field of nuclear medicine and oncology offering state-of-the-art solutions. EDH currently handles sales and marketing of selected radiopharmaceuticals and radioisotopes as well as sales and after sales support of equipment used in nuclear medicine and niche segments of oncology. EDH also offers turnkey setup of radiopharmaceutical manufacturing plants and nuclear medicine departments compliant to EU/USFDA cGMP.


About SHINE Medical Technologies


SHINE is a nuclear technology company committed to improving the lives of patients around the world. The company is focused initially on the commercialization of medical isotopes, including molybdenum-99, a diagnostic isotope used to diagnose heart disease, cancer and other diseases, and lutetium-177, a therapeutic isotope that holds the promise of significantly improving the outcomes for some cancer patients. SHINE has created isotope production processes that will deliver products to benefit physicians and patients and help solve critical supply problems in the United States and markets in Europe and around the world. SHINE has a long-term strategy to solve some of humanity’s biggest problems and advance our vision for progressively broad and impactful uses of nuclear technology. For more information, please visit our website at